Feasibility Study of Imaging Omics Model Based on Different Machine Learning Models to Predict Molecular Typing and Expression of Glioma Before Surgery

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200055563

Enrollment

Unknown

Registered

2022-01-12

Start date

2022-01-10

Completion date

Unknown

Last updated

2023-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant tumor

Interventions

Gold Standard:The pathological report

Index test:IDH&#32

mutation&#32

state,&#32

1P&#32

/&#32

19Q&#32

combined&#32

deletion,&#32

MGMT&#32

methylation

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients with glioma diagnosed by postoperative pathology (WHO central Nervous system Tumor Classification 2016); 2. Patients with initial diagnosis and treatment; 3. No preoperative radiotherapy or chemotherapy was performed; 4. Conventional brain MRI examination within 1 week before surgery with complete MRI image sequence: T1WI, T1 enhanced sequence (T1CE), T2WI, T2 FLAIR; 5. No serious comorbidities, no other malignant tumors.

Exclusion criteria

Exclusion criteria: 1. Patients with poor image quality and unable to meet the requirements of software processing; 2. Patients who had received needle biopsy before routine BRAIN MRI examination.

Design outcomes

Primary

Measure	Time frame
IDH;1p/19q;MGMT methylation;T1WI;T1CE;T2WI;T2 FLAIR;accuracy, sensitivity, specificity;	—

Countries

China

Contacts

Public ContactLin Zheng

Department of Radiation Oncology, Taizhou Tumor Hospital

y215180575@zju.edu.cn+86 15258602261

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026